company background image
ELYM

Eliem Therapeutics NasdaqGM:ELYM Stock Report

Last Price

US$2.62

Market Cap

US$69.6m

7D

-6.7%

1Y

-75.4%

Updated

04 Dec, 2022

Data

Company Financials +
ELYM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ELYM Stock Overview

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems.

Eliem Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eliem Therapeutics
Historical stock prices
Current Share PriceUS$2.62
52 Week HighUS$14.98
52 Week LowUS$2.47
Beta0
1 Month Change-15.70%
3 Month Change-12.61%
1 Year Change-75.36%
3 Year Changen/a
5 Year Changen/a
Change since IPO-83.51%

Recent News & Updates

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Nov 18
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Aug 15

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Aug 02

Recent updates

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Nov 18
We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Shareholder Returns

ELYMUS BiotechsUS Market
7D-6.7%4.2%1.5%
1Y-75.4%-7.4%-14.9%

Return vs Industry: ELYM underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: ELYM underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is ELYM's price volatile compared to industry and market?
ELYM volatility
ELYM Average Weekly Movement12.4%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: ELYM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ELYM's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201843Bob Azelbyhttps://www.eliemtx.com

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder.

Eliem Therapeutics, Inc. Fundamentals Summary

How do Eliem Therapeutics's earnings and revenue compare to its market cap?
ELYM fundamental statistics
Market CapUS$69.65m
Earnings (TTM)-US$48.03m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ELYM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$48.03m
Earnings-US$48.03m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.81
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ELYM perform over the long term?

See historical performance and comparison